Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.29 +1.58%

+$0.15 today

Market cap
$941.21M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 3.16M

Average 0.46M

IMTX EBITDA Margin

EBITDA as a percentage of revenue.

Immatics N.V.NASDAQ: IMTX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -719.6%

EBITDA Margin was -719.6% in Q1 FY2026, down 518.0 pp from a year earlier. On a trailing-twelve-month basis it was -542.7%, down 539.6 pp year over year. Over 3 fiscal years it narrowed by 412.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -652.0% for the fiscal year ending Dec 2026, down from -383.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-719.6%-556.8 pp QoQ
Last fiscal yearDec 2025
-383.5%-405.6 pp YoY
LTMMar 2026
-542.7%-539.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-518.0 pp+883.0 pp+1401.0 pp
1 year-405.6 pp-268.5 pp+137.1 pp
3 years-412.4 pp+190.0 pp+602.5 pp
5 years+378.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-383.5%
Year-over-year change
-405.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IMTX compares with its peers on the latest reported figures

  • IMTX's LTM Mar 2026 EBITDA Margin of -542.7% is the 8th highest of the 10 companies compared; the peer median is -75.1%.
  • Its year-over-year change of -539.6 pp is the 9th highest of 10, against a peer median of -6.9 pp.
  • Over three fiscal years its change of -412.4 pp compares with a peer median of +26.7 pp.
IMTX Competitors Peer median
EBITDA Margin for IMTX and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
IMCRImmunocore Holdings plcLTM Mar 20261.6% +1.6 pp+26.7 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-23.7% -20.8 pp+381.6 pp
BNTXBioNTech SELTM Jun 2026-35.6% -34.2 pp-98.4 pp
CLLSCellectis S.A.LTM Mar 2026-75.1% -6.9 pp+343.8 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-89.7% -57.3 pp+126.4 pp
JANXJanux Therapeutics, Inc.LTM Mar 2026-520.3% +290.5 pp-393.5 pp
IMTXImmatics N.V.LTM Mar 2026-542.7% -539.6 pp-412.4 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1298.7% +1519.2 pp-759.6 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-770932.3% -482924.6 pp-730107.8 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding IMTX) -75.1%-6.9 pp+26.7 pp

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.